Xeroderma (ocular) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Xeroderma (ocular), also called ocular surface dryness or dry eye disease (DED), is a chronic condition in which the eye’s surface does not produce enough tears—or the tears evaporate too quickly—to keep the cornea and conjunctiva adequately lubricated. The term “xeroderma” comes from the Greek words “xero” (dry) and “derma” (skin), reflecting the skin‑like epithelium that lines the ocular surface.

While the condition can affect anyone, it is most common in:

• Women, especially those over 50 years of age.
• Individuals who spend many hours in front of computer screens or in low‑humidity environments.
• People with autoimmune diseases such as Sjögren’s syndrome, rheumatoid arthritis, or lupus.
• Contact‑lens wearers and those who have undergone refractive surgery (e.g., LASIK).

Global prevalence estimates range from 5% to 30% of the adult population, with higher rates in older adults (up to 65% in people >75 years). In the United States, the American Academy of Ophthalmology cites roughly 16 million adults living with dry eye disease (Mayo Clinic, 2023).

Symptoms

Symptoms can be intermittent or constant, and often worsen in certain environments (wind, air‑conditioning, smoke). The following list captures the full spectrum of patient‑reported experiences:

• Foreign‑body sensation – feeling of grit or sand in the eye.
• Burning or stinging – often described as “eye fire.”
• Itching – may be confused with allergic conjunctivitis.
• Redness (hyperemia) – due to ocular surface inflammation.
• Blurred vision – especially after prolonged reading or screen use; vision typically clears with blinking.
• Excessive tearing – paradoxically, the eye may produce reflex tears as a protective response.
• Light sensitivity (photophobia) – discomfort in bright environments.
• Difficulty wearing contact lenses – intolerance or frequent removal.
• Eye fatigue – a heavy‑feeling after visual tasks.
• Stringy mucus discharge – especially upon waking.

Causes and Risk Factors

Primary Mechanisms

Dry eye disease is multifactorial. The three main pathogenic pathways are:

1. Aqueous‑tear deficiency – reduced production by the lacrimal glands, often linked to aging or autoimmune disease.
2. Evaporative dry eye – excessive tear evaporation due to Meibomian gland dysfunction (MGD), environmental factors, or eyelid abnormalities.
3. Ocular surface inflammation – a self‑perpetuating cycle where inflammation further impairs tear film stability.

Key Risk Factors

• Age: Tear production declines ~0.5 mL/year after age 40.
• Sex hormones: Post‑menopausal estrogen decline is associated with reduced tear film quality.
• Medications: Antihistamines, decongestants, antidepressants, β‑blockers, and isotretinoin decrease tear secretion.
• Systemic diseases: Sjögren’s syndrome (affects up to 90% of patients), rheumatoid arthritis, diabetes, thyroid disease.
• Environmental exposures: Low humidity, wind, air‑conditioning, smoke, and prolonged digital device use.
• Ocular surgeries: LASIK, cataract extraction, or ptosis repair can disrupt corneal nerves.
• Contact lens wear: Especially extended‑wear or low‑oxygen‑permeability lenses.

Diagnosis

Diagnosis is clinical, based on history, symptom questionnaires, and objective tests. The most widely used symptom tool is the Ocular Surface Disease Index (OSDI), a 12‑question survey scoring severity from 0 (none) to 100 (severe).

Common Clinical Tests

1. Schirmer I test – measures basic tear production using a filter paper strip placed under the lower eyelid for 5 minutes. ≤5 mm wetting suggests aqueous deficiency.
2. Fluorescein staining – dye highlights corneal epithelial defects; graded by the Oxford or NEI scale.
3. Tear Break‑Up Time (TBUT) – the interval between a blink and the first appearance of a dry spot, assessed after fluorescein instillation. <8 seconds is abnormal.
4. Meibography – infrared imaging of Meibomian glands to detect dropout or obstruction.
5. Lipid layer thickness – measured with interferometry; thin lipid layers point to evaporative dry eye.
6. Osmolarity testing (e.g., TearLab) – tear osmolarity >308 mOsm/L is diagnostic for DED.
7. Inflammatory marker assays – matrix metalloproteinase‑9 (MMP‑9) point‑of‑care test (InflammaDry) indicates ocular surface inflammation.

In refractory cases, an ophthalmologist may order imaging (e.g., anterior segment OCT) or rule out other conditions (infection, blepharitis, allergic conjunctivitis).

Treatment Options

Therapy is stepwise, targeting the underlying mechanism and breaking the inflammation‑tear cycle.

1. Lifestyle & Environmental Modifications

• Follow the 20‑20‑20 rule during screen work: every 20 minutes, look at something 20 feet away for 20 seconds.
• Use a humidifier (maintain indoor humidity 40‑60%).
• Wear wraparound sunglasses outdoors to reduce wind‑evaporation.
• Avoid direct airflow from fans, air‑conditioners, or heaters.

2. Over‑the‑Counter (OTC) Lubricants

• Artificial tears – preservative‑free options (e.g., Systane Ultra, Refresh Optive) are preferred for frequent use.
• Ointments or gels – thicker formulations for nighttime use.
• Lipids‑containing drops – e.g., Refresh Optive Mega‑HD, restore tear film lipid layer.

3. Prescription Medications

1. Anti‑inflammatory agents
   • Cycloplegic steroid eye drops (short‑term) for acute inflammation.
   • Cyclosporine A 0.05 % (Restasis) – improves tear production by reducing T‑cell mediated inflammation; may take 4‑6 weeks for effect.
   • Lifitegrast 5 % (Xiidra) – blocks LFA‑1/ICAM‑1 interaction, reducing ocular surface inflammation; works within weeks.
2. Secretagogues
   • Oral pilocarpine or cevimeline – stimulate lacrimal secretion; used mainly for Sjögren’s patients.
3. Topical antibiotics or steroid‑antibiotic combos – indicated when blepharitis or meibomian gland infection contributes to evaporative dry eye.

4. Procedural Interventions

• Punctal plugs – silicone or collagen plugs inserted into the lacrimal puncta to retain tears; reversible and effective for many patients.
• Meibomian gland expression (MGX) – manual or thermal massage to unblock lipid glands.
• Thermal pulsation devices (e.g., LipiFlow) – deliver controlled heat and pressure to clear obstructed glands.
• Intense Pulsed Light (IPL) therapy – reduces inflammation and improves gland function, especially in rosacea‑associated dry eye.
• Autologous serum eye drops – for severe refractory cases; contain growth factors similar to natural tears.

5. Emerging Therapies

Research is ongoing into novel agents such as recombinant human lubricin, nano‑emulsion eye drops, and gut‑microbiome modulation. Participation in clinical trials may be an option for select patients (ClinicalTrials.gov, 2024).

Living with Xeroderma (ocular)

Effective self‑management can dramatically improve quality of life.

• Schedule regular follow‑ups (every 6–12 months) with an eye‑care specialist to monitor disease progression.
• Maintain a symptom diary – note triggers, severity scores, and response to treatments.
• Stay hydrated – aim for at least 2 L of water per day.
• Use omega‑3 fatty acid supplements (e.g., fish oil 1000 mg daily) which have modest benefit in reducing evaporative dry eye (Cochrane Review, 2022).
• Practice eyelid hygiene – warm compresses for 5–10 minutes followed by gentle lid scrubs with diluted baby shampoo or commercial lid wipes.
• Adjust contact lens wear – switch to high‑oxygen‑permeability lenses, limit wear time, and consider daily disposables.
• Optimize indoor air quality – use HEPA filters, avoid smoking, and keep pets away from sleeping areas if they cause allergen‑related irritation.

Prevention

While not all cases are preventable, risk can be lowered by adopting the following habits:

• Take regular breaks during screen time (20‑20‑20 rule).
• Wear protective eyewear in dusty or windy environments.
• Limit or substitute medications known to reduce tear production; discuss alternatives with a physician.
• Control systemic diseases (e.g., maintain good glycemic control in diabetes).
• Seek early evaluation for symptoms of Sjögren’s or other autoimmune disorders.

Complications

If left untreated, chronic ocular surface dryness can lead to:

• Corneal epithelial breakdown – persistent staining, ulceration, and increased infection risk.
• Scarring or neovascularization – may impair vision permanently.
• Reduced visual acuity – due to irregular tear film and surface irregularities.
• Increased risk of microbial keratitis – especially in contact‑lens wearers.
• Psychosocial impact – chronic discomfort can cause anxiety, depression, and decreased productivity.

When to Seek Emergency Care

References

• Mayo Clinic. “Dry eye.” Updated 2023. https://www.mayoclinic.org
• American Academy of Ophthalmology. “Dry Eye Disease Preferred Practice Pattern.” 2022.
• National Eye Institute (NEI). “Facts About Dry Eye.” 2023.
• World Health Organization. “Global Prevalence of Dry Eye Disease.” WHO Report, 2022.
• Cochrane Database of Systematic Reviews. “Omega‑3 supplementation for dry eye disease.” 2022.
• Centers for Disease Control and Prevention. “Sjogren’s Syndrome.” 2024.
• ClinicalTrials.gov. Ongoing studies of novel dry‑eye therapies. Accessed May 2026.

```